Welcome to our dedicated page for Medmix news (Ticker: MDMXF), a resource for investors and traders seeking the latest updates and insights on Medmix stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Medmix's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Medmix's position in the market.
medmix (SIX: MEDX) reported H1 2025 results showing improved profitability despite revenue challenges. Revenue declined to CHF 225.4 million (-6.5% YoY), with Healthcare segment growing 7.5% while Consumer & Industrial segment declined 10.9% organically.
Key financial metrics include adjusted EBITDA margin of 19.9% (+80 bps YoY), segment gross profit margin improvement of 390 bps to 47.9%, and Free Cash Flow of CHF 11.4m (+50.9% YoY). The company's Growth and Efficiency program secured CHF 15 million in savings, with CHF 8.5m realized in H1 2025.
Management revised 2025 revenue guidance to expect a decline similar to H1 2025, while maintaining adjusted EBITDA margin guidance of 18-19%. Mid-term guidance remains unchanged with revenue CAGR above 4% and adjusted EBITDA margin above 20%.
medmix (MDMXF) has achieved a significant environmental milestone by being named one of only nine Swiss companies to receive an "A" score in CDP's annual climate change assessment. The company also earned an "A-" score for water security, placing it among Switzerland's environmental leaders including Novartis, ABB, Swisscom, and Georg Fischer. This achievement is particularly notable as only 2% of nearly 23,000 companies evaluated globally by CDP received an "A" score.
CEO René Willi emphasized the company's strategic commitment to environmental management and transparent reporting. medmix, headquartered in Baar, Switzerland, operates 14 production sites worldwide with approximately 2,700 employees and holds over 900 active patents in high-precision delivery devices for healthcare, consumer, and industrial markets.
FAQ
What is the market cap of Medmix (MDMXF)?
